Hemoglobinopathies: Clinical Trials

150 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

69 completed, 31 terminated, 17 unknown, 15 recruiting. 150 Phase 3, 34 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3150Completed 69, Terminated 31, Unknown 17, Recruiting 15, Not yet recruiting 7, Active not recruiting 6, Withdrawn 4, Enrolling by invitation 1
Phase 234Completed 19, Unknown 11, Recruiting 2, Active not recruiting 1, Terminated 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 150 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Exa-cel - Sickle Cell Disease
Phase 3WithdrawnVertex Pharmaceuticals Incorporated2027-07-312026-03-25
Glutamine Early Start in Children With SCD Younger Than Five
Glutamine, Standard of Care (SOC) - Sickle Cell Disease (SCD)
Phase 3Not yet recruitingAin Shams University702026-12-012026-11-17
Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia
Thalidomide, Danazol, Prednisolone - Beta-Thalassemia, Thalassemia
Phase 3RecruitingKhyber Medical University Peshawar1722026-10-122026-10-21
Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease
Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease
Phase 3Not yet recruitingUniversity Hospital, Rouen1442026-09-012026-03-27
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Mitapivat Matched Placebo, Mitapivat - Sickle Cell Disease
Phase 3RecruitingAgios Pharmaceuticals, Inc.1592026-07-212026-10-28
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease
Phase 3RecruitingNantes University Hospital1042026-07-032026-09-09
Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department
Parecoxib, Morphine - Sickle-Cell Disease with Crisis
Phase 3Not yet recruitingOman Medical Speciality Board2262026-05-012025-03-20
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD)
Phase 2 / Phase 3RecruitingYves Pastore292026-02-032026-08-21
Optimal Timing of Ketamine Initiation for SCD Pain
Ketamine hydrochloride injection, Placebo - Sickle Cell Disease, Sickle Cell Crisis
Phase 3Not yet recruitingBoston Children's Hospital902026-02-012026-03-09
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
PCV21, 20vPCV - Sickle Cell Disease
Phase 3RecruitingSanofi1002026-01-202026-04-15
Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
Iron chelating intervention, N Acetyl cysteine 600mg, Alpha Lipoic Acid 600 MG Oral Tablets - Beta Thalassemia
Phase 3Not yet recruitingTanta University662025-08-302025-09-05
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1302025-08-272026-06-24
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Rilzabrutinib, Placebo - Sickle Cell Disease
Phase 3RecruitingSanofi1922025-08-122026-11-18
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
L-citrulline, Placebo - Sickle Cell Disease
Phase 3Not yet recruitingAsklepion Pharmaceuticals, LLC1202025-07-252025-05-29
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Etavopivat, Placebo - Sickle Cell Disease
Phase 3RecruitingNovo Nordisk A/S5102025-02-172026-09-17
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
zinc sulfate, Placebo - Sickle Cell Disease
Phase 2 / Phase 3CompletedIndiana University1002025-02-102026-01-30
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Etavopivat A, Etavopivat B, Etavopivat C - Sickle Cell Disease, Thalassemia
Phase 3RecruitingNovo Nordisk A/S4802025-01-102026-09-18
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Crizanlizumab, Placebo - Sickle Cell Disease
Phase 3RecruitingNovartis Pharmaceuticals3542024-10-242026-11-10
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric
Sufentanil - Vaso-occlusive Crisis
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris1822024-05-022023-12-26
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Hydroxyurea - Sickle Cell Anemia in Children, Sickle Cell Disease
Phase 3RecruitingBrown University4002023-11-152026-08-20

Showing 20 of 150. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (108)  ·  beta-Thalassemia (32)  ·  Vaso-Occlusive Crises (26)  ·  Hematologic Diseases (19)  ·  Thalassemia (19)  ·  Iron Overload (9)  ·  Acute Chest Syndrome (7)  ·  Genetic Diseases, Inborn (6)  ·  Sickle Cell Trait (6)  ·  Stroke (6)  ·  Agnosia (5)  ·  Anemia (5)  ·  Pain (5)  ·  Hypertension, Pulmonary (4)

Broader conditions

Anemia, Hemolytic, Congenital (150)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (150)  ·  Hemic and Lymphatic Diseases (150)  ·  Anemia, Hemolytic (149)  ·  Anemia (145)  ·  Genetic Diseases, Inborn (144)  ·  Hematologic Diseases (131)  ·  Thalassemia (24)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Metabolic Diseases (14)  ·  Nervous System Diseases (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Respiratory Tract Diseases (14)  ·  Lung Diseases (13)

Interventions

Hydroxyurea (17)  ·  Deferasirox (9)  ·  exagamglogene autotemcel (7)  ·  Deferoxamine (6)  ·  Deferiprone (5)  ·  voxelotor (5)  ·  Blood Transfusion (4)  ·  Docosahexaenoic Acids (4)  ·  Morphine (4)  ·  Thalidomide (4)  ·  Amlodipine (3)  ·  Bosentan (3)  ·  Glutamine (3)  ·  Isoflurophate (3)  ·  Ketamine (3)

Sponsors

Pfizer (11)  ·  Assistance Publique - Hôpitaux de Paris (8)  ·  Ain Shams University (7)  ·  Novartis Pharmaceuticals (7)  ·  Vertex Pharmaceuticals Incorporated (7)  ·  National Heart, Lung, and Blood Institute (NHLBI) (4)  ·  Actelion (3)  ·  Children's Hospital Medical Center, Cincinnati (3)  ·  Genetix Biotherapeutics Inc. (3)  ·  Indiana University (3)  ·  Mast Therapeutics, Inc. (3)  ·  Agios Pharmaceuticals, Inc. (2)  ·  AstraZeneca (2)  ·  Augusta University (2)  ·  Beni-Suef University (2)

Countries

United States (66)  ·  United Kingdom (31)  ·  France (28)  ·  Italy (28)  ·  Egypt (24)  ·  Canada (21)  ·  Turkey (Türkiye) (20)  ·  Brazil (19)  ·  Germany (18)  ·  Lebanon (18)  ·  Oman (16)  ·  Kenya (15)  ·  Nigeria (15)  ·  Saudi Arabia (15)  ·  Belgium (13)

Top investigators

Michael R. DeBaun, MD, MPH (3)  ·  Russell E. Ware, MD, PhD (3)  ·  Ahmed F Mahmoud Hussein, MS.c (2)  ·  Anders Berggren, MD, PhD (2)  ·  Charles Quinn, MD (2)  ·  Claudia Morris, MD (2)  ·  Donald Brambilla (2)

Results publications

PMID 37975597, PMID 37254256, PMID 20175775, PMID 19721013, PMID 30952488, PMID 33283989, PMID 34175041, PMID 35981565, PMID 38775255, PMID 40857358, PMID 40862696, PMID 42252696, PMID 42274009, PMID 16382063, PMID 17951527, PMID 18055982, PMID 18351337, PMID 18478575, PMID 19621454, PMID 19813252, PMID 19856395, PMID 19880138, PMID 19951979, PMID 19996412, PMID 20424435, PMID 20566896, PMID 20797449, PMID 21071497, PMID 21179892, PMID 21217080, PMID 21523806, PMID 21571150, PMID 21606305, PMID 21744485, PMID 21826782, PMID 21848879, PMID 22180427, PMID 22190441, PMID 22294512, PMID 22318199, PMID 22915643, PMID 23539110, PMID 23585526, PMID 23585527, PMID 23861242, PMID 23927461, PMID 23999955, PMID 24276838, PMID 24443249, PMID 24529619

NIH funding

2019 (4), 2023 (4), 2017 (2), 2004 (1), 2025 (1), K23HL136787 (1), N01HB07150 (1), N01HB07151 (1), N01HB07152 (1), N01HB07153 (1), N01HB07154 (1), N01HB07155 (1), N01HB07156 (1), N01HB07157 (1), N01HB07158 (1)